- Health Topics
- The Science
- Grants and Training
- News and Events
- About NHLBI
COVID-19 guidance
NHLBI's Research Strategy
COVID-19 affects all of us, with the heaviest toll on those with preexisting heart, lung, and blood conditions and populations who are vulnerable to these conditions. Our research strategy aims to understand and address risk factors for the disease, develop prevention and treatment strategies, and find ways to hasten and enhance recovery.
Related News
NIH builds large nationwide study population of tens of thousands to support research on long-term effects of COVID-19
The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City...
COVID-19: A Big Test for Hematology Trainees
When COVID-19 restrictions closed research laboratories across the country, it meant Erik Kimble, M.D.’s hematology and oncology training came to a virtual crawl. Not surprisingly, Kimble, who completed medical school in Mexico at the height of the swine flu pandemic, was overwhelmed yet again with uncertainty. He spent months preparing for his...
NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in February 2021 due to lack of efficacy...
